NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $37.98 -2.06 (-5.14%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$37.73▼$40.3550-Day Range$20.85▼$44.2252-Week Range$7.60▼$44.80Volume323,100 shsAverage Volume907,071 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5.3% Upside$40.00 Price TargetShort InterestHealthy12.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.52 out of 5 starsMedical Sector855th out of 910 stocksPharmaceutical Preparations Industry399th out of 426 stocks 1.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 2 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.12% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Harrow has recently decreased by 20.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 1.4 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Harrow this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders13.67% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.38) to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -41.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -41.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 23.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Harrow Stock (NASDAQ:HROW)Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesSeptember 3, 2024 | finance.yahoo.comHarrow to Present at Three Investor Conferences in September in New YorkAugust 30, 2024 | americanbankingnews.comHarrow (NASDAQ:HROW) Given "Buy" Rating at B. RileySeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | msn.comChart of the Day: Harrow - Eye Care PharmaAugust 27, 2024 | finance.yahoo.comHROW Sep 2024 43.000 put (HROW240920P00043000)August 27, 2024 | finance.yahoo.comHROW Sep 2024 55.000 call (HROW240920C00055000)August 21, 2024 | seekingalpha.comBorrowing Cash To Burn It: The Curious Case Of HarrowAugust 16, 2024 | seekingalpha.comHarrow: Bulls On ParadeSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 10, 2024 | lse.co.ukHarrow Share Price (HROW.US)August 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)August 9, 2024 | wsj.comHarrow Inc.August 9, 2024 | seekingalpha.comHarrow, Inc. (HROW) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | benzinga.comUnpacking the Latest Options Trading Trends in HarrowAugust 9, 2024 | msn.comHarrow Health, Inc. (NASDAQ:HROW) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comHarrow, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 8, 2024 | finanznachrichten.deHarrow Health, Inc. Announces Second Quarter 2024 Financial ResultsJuly 31, 2024 | markets.businessinsider.comHarrow Health’s Strong Market Performance and Growth Prospects Justify Buy RatingSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+5.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-21.78% Pretax Margin-20.71% Return on Equity-40.59% Return on Assets-8.93% Debt Debt-to-Equity Ratio3.18 Current Ratio2.60 Quick Ratio2.43 Sales & Book Value Annual Sales$130.19 million Price / Sales10.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book23.16Miscellaneous Outstanding Shares35,480,000Free Float30,545,000Market Cap$1.35 billion OptionableOptionable Beta0.75 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOKindred BiosciencesNASDAQ:KINLifeVantageNASDAQ:LFVNBridgeBio PharmaNASDAQ:BBIONuvalentNASDAQ:NUVLView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPSold 3,000 shares on 8/16/2024Ownership: 0.000%Creative PlanningBought 14,500 shares on 8/16/2024Ownership: 0.083%Millennium Management LLCSold 20,941 shares on 8/15/2024Ownership: 0.389%Deerfield Management Company L.P. Series CBought 9,105 shares on 8/15/2024Ownership: 0.072%The Manufacturers Life Insurance Company Bought 567 shares on 8/15/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $11.20 on January 1st, 2024. Since then, HROW stock has increased by 239.1% and is now trading at $37.98. View the best growth stocks for 2024 here. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. The business had revenue of $48.94 million for the quarter, compared to analysts' expectations of $42.78 million. Harrow had a negative trailing twelve-month return on equity of 40.59% and a negative net margin of 21.78%. Who are Harrow's major shareholders? Top institutional investors of Harrow include Renaissance Technologies LLC (0.87%), Rice Hall James & Associates LLC (0.72%), Westside Investment Management Inc. (0.59%) and Susquehanna International Group LLP. Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CymaBay Therapeutics (CBAY). This page (NASDAQ:HROW) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.